YolTech Therapeutics completes over 300 million Yuan in Series B financing to develop in vivo gene editing drugs

Sep 10, 2025 22:02 CST Updated Sep 11, 16:55

YolTech Therapeutics

mRNA Drug and Gene Editing Drug Developer

AZ-CICC Fund

Equity Investment Firms

Green Pine Capital

Venture Capital Management Institution

KHK FUND

Investment Institutions in the Hard Technology Sector

K2 Bio Partners

Internet and Healthcare Growth-Stage Investment Fund

Yuanyi

Alternative Asset Investment Platform

Decheng Capital

Life Sciences Investment Firms

September 10, Shanghai – AstraZeneca CICC Healthcare Fund announced today the completion of leading YolTech Therapeutics’ Series B financing round, with a total amount exceeding 300 million RMB (approximately 45 million USD). This round of financing also receivedGreen Pine Capital, Tianjin Venture Capital Management Co.,ltd., and Xinneng Venture Capital, as well as Tibet Xianfeng Qiyun Investment Advisory Co., Ltd.,Yuanyi (Shanghai) Investment Management LLPand Decheng Capital's additional follow-on investment. Thus, YolTech Therapeutics has accumulated over 575 million RMB in financing.

YolTech Therapeutics is a high-tech biopharmaceutical company focused on developing in vivo gene editing drugs based on mRNA-LNP delivery technology. Currently, all four of YolTech Therapeutics' product pipelines have entered the clinical stage, making it the company with the most clinical-stage pipelines in the field of in vivo gene editing drugs globally. This fully demonstrates the tremendous value and potential of China's local innovation, aligning closely with the investment philosophy of Wuxi AstraZeneca CICC Venture Capital Partnership (Limited Partnership), which is committed to supporting cutting-edge medical innovations and promoting local enterprises to go global.

YOLT-101 has achieved positive results in an exploratory clinical study (NCT06458010) initiated by Renji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and conducted in collaboration with YolTech Therapeutics. Study data show that YOLT-101, a next-generation in vivo base editing therapy independently developed by YolTech, utilizes its proprietary adenine base editor YolBE hpABE5 and a novel LNP delivery system. With just a single injection, it can safely and effectively reduce low-density lipoprotein cholesterol (LDL-C) levels in patients with familial hypercholesterolemia (FH), demonstrating favorable safety and sustained efficacy.YOLT-101 has been approved for clinical trials in China, and Salubris Pharma has obtained the rights for research, development, and commercialization in China.

Core pipeline YOLT-201 achieved excellent data in the IIT clinical study for treating transthyretin amyloid cardiomyopathy (ATTR-CM). In the high-dose group, serum TTR levels were reduced by approximately 90% after a single dose, with rapid, sustained, and stable declines, demonstrating good safety and tolerability; patients in the low-dose group who did not reach the target reduction in TTR received a second dose, after which serum TTR levels decreased to near-complete clearance.

YOLT-201 is a new generation of in vivo gene editing drug independently developed by YolTech Therapeutics. It delivers the CRISPR-Cas gene editing RNA system through lipid nanoparticles (LNP) to achieve highly efficient and specific transthyretin (TTR) target gene editing in human liver, permanently reducing TTR protein levels in the blood. This offers the potential for lifelong treatment of Transthyretin Amyloidosis (ATTR), providing ATTR patients with a revolutionary solution from "slowing disease progression" to "complete cure."

YOLT-203 is an innovative in vivo gene-editing drug that utilizes YolCas12HF, a CRISPR/Cas gene-editing tool independently developed by YolTech Therapeutics, and is precisely delivered to hepatocytes through a self-developed lipid nanoparticle (LNP) system. It targets the editing of the HAO1 gene, suppressing glycolate oxidase (GO) expression, thereby reducing oxalate production at the source. This offers the potential for "one-time treatment, lifelong cure," providing new hope for patients with Primary Hyperoxaluria Type 1 (PH1).

YOLT-202 is based on YolBE, a next-generation adenine base editor independently developed by YolTech Therapeutics. This editor utilizes a novel deaminase derived from Hafnia paralvei and has undergone three years of development and optimization through YolTech Therapeutics' high-throughput gene editor evolution platform.MostFinally, it has achieved excellent editing efficiency and precision. YolBE can efficiently and accurately repair genes at the SERPINA1 PiZ site while almost completely avoiding bystander editing of surrounding bases, providing a "one-shot cure" new approach for AATD treatment.